Roivant Sciences Ltd. (30)

Browse by Contract Category

Contracts

Amendment No. 1 to License and Collaboration Agreement, dated as of June 10, 2022, by and between Pfizer Inc. and Priovant, Inc (Filed With SEC on June 28, 2022)
Investor Rights Agreement, dated as of September 13, 2021, by and among Priovant Holdings, Inc., Roivant Sciences Ltd. and Pfizer Inc (Filed With SEC on June 28, 2022)
Amendment No. 1 to the Business Combination Agreement, dated June 9, 2021, by and among Montes Archimedes Acquisition Corp., Roivant Sciences Ltd. and Rhine Merger Sub, Inc (Filed With SEC on June 28, 2022)
Exclusive License Agreement by and between Eisai Co. Ltd. and Pharmavant 7 GmbH, dated as of November 24, 2021 (Filed With SEC on February 14, 2022)
Bonus Award Letter from Roivant Sciences Inc. to Benjamin Zimmer, dated as of December 21, 2021 (Filed With SEC on December 22, 2021)
Amendment No. 2 to the Sponsor Support Agreement, dated as of September 30, 2021, among Roivant, MAAC, MAAC Sponsor and the other parties thereto (Filed With SEC on October 1, 2021)
License and Collaboration Agreement, dated as of September 13, 2021, by and between Pfizer Inc. and Priovant, Inc (Filed With SEC on June 28, 2022)
Amendment No. 1 to the Support Agreement, dated as of June 9, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp., Patient Square Capital LLC and certain... (Filed With SEC on June 28, 2022)
Form of Transaction Support Agreement, dated as of May 1, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp. and certain shareholders of Roivant... (Filed With SEC on June 28, 2022)
Sponsor Support Agreement, dated as of May 1, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp., Patient Square Capital LLC and certain shareholders of... (Filed With SEC on June 28, 2022)
Form of Subscription Agreement (Filed With SEC on June 28, 2022)
Third Amended and Restated Registration Rights Agreement, dated as of May 1, 2021, by and among Roivant Sciences Ltd. and the parties thereto (Filed With SEC on June 28, 2022)
Business Combination Agreement, dated as of May 1, 2021, by and among Montes Archimedes Acquisition Corp., Roivant Sciences Ltd. and Rhine Merger Sub, Inc (Filed With SEC on June 28, 2022)
Common Shares Purchase Agreement, dated February 14, 2022, between Roivant Sciences Ltd. and CF Principal Investments LLC (Filed With SEC on February 14, 2022)
Third Amendment to Cross License Agreement, dated December 9, 2021, by and between Genevant Sciences GmbH and Arbutus Biopharma Corporation (Filed With SEC on December 22, 2021)
Agreement and General Release Between Roivant Sciences Ltd., Roivant Sciences, Inc. and Benjamin Zimmer (Filed With SEC on November 15, 2021)
Asset Purchase Agreement, dated as of May 29, 2012, by and between Glaxo Group Limited and Welichem Biotech Inc (Filed With SEC on May 14, 2021)
Executive Employment Agreement between Roivant Sciences, Inc. and Benjamin Zimmer, dated as of May 14, 2021 (Filed With SEC on May 14, 2021)
Executive Employment Agreement between Roivant Sciences, Inc. and Eric Venker, dated as of May 14, 2021 (Filed With SEC on May 14, 2021)
Executive Employment Agreement between Roivant Sciences, Inc. and Matthew Gline, dated as of May 14, 2021 (Filed With SEC on May 14, 2021)
Amended and Restated Employment Agreement between Roivant Sciences, Inc. and Vivek Ramaswamy, dated as of May 14, 2021 (Filed With SEC on May 14, 2021)
Form of Roivant Sciences Ltd. 2021 Equity Incentive Plan (Filed With SEC on May 14, 2021)
Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan (Filed With SEC on May 14, 2021)
First Amendment to Funding Agreement dated as of October 11, 2018, by and between Dermavant Sciences GmBH and NovaQuest Co-Investment Fund VIII, L.P (Filed With SEC on May 14, 2021)
Funding Agreement, dated as of July 10, 2018, by and between Demavant Sciences GmBH and NovaQuest Co-Investment Fund VIII, L.P (Filed With SEC on May 14, 2021)
Commercial Supply and Manufacturing Agreement, dated April 1, 2019, by and between Dermavant Sciences GmbH and GlaxoSmithKline (Filed With SEC on May 14, 2021)
Clinical Supply and Manufacturing Agreement, dated August 20, 2018, by and between Dermavant Sciences GmbH and GlaxoSmithKline (Filed With SEC on May 14, 2021)
Collaboration and License Agreement, dated as of January 15, 2020, by and between Dermavant Sciences GmbH and Japan Tobacco Inc (Filed With SEC on May 14, 2021)
First Amendment to the Asset Purchase Agreement, dated as of August 31, 2012, by and between Glaxo Group Limited and Welichem Biotech, Inc (Filed With SEC on May 14, 2021)
Asset Purchase Agreement, dated as of July 10, 2018, by and among GlaxoSmithKline Intellectual Property Development Ltd., Glaxo Group Limited and Dermavant Sciences GmBH (Filed With SEC on May 14, 2021)